SEC Form 4 · accession 0001552781-26-000501
enGene Therapeutics Inc. · ENGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Grossman
Officer — Interim Chief Medical Officer · Director
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 4:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001980845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Sep 22, 2026 | P | 5,102 | $1.97 | A | 5,102 | D |
Table II — derivative securities
No Table II lines on this filing.